UC researchers have discovered a new therapy for transplant patients that targets the antibody-producing plasma cells that can cause organ rejection.
Results of the study are published in the Dec. 27, 2008, edition of the journal Transplantation.
Steve Woodle, MD, and colleagues found that a cancer drug—bortezomib—used to treat multiple myeloma, or cancer of the plasma cells, is effective in treating rejection episodes caused by antibodies that target transplanted kidneys and reversing rejection episodes that did not respond to standard therapies.
B-lymphocytes, or B cells, play a large role in the humoral immune response by making immune proteins that attack transplanted organs.
“We found a body of literature demonstrating that bortezomib works well in suppressing transplant rejection in the laboratory,” says Woodle, lead author of the study, professor of surgery and chief of transplant surgery at UC. “Moreover, it worked well in models of autoimmune diseases.”
T-lymphocytes, or T cells, are white blood cells that were commonly thought to cause the rejection of transplanted organs.
Woodle and his team began searching for agents that targeted plasma cells in 2005.
“It has become clear that plasma cells and the antibodies they produce play a bigger role in rejection than previously thought, and the development of therapies targeting these cells has lagged,” he says. “We realized that current therapies don’t target the plasma cells that may produce the antibody.”
Researchers administered this drug to six kidney transplant recipients with treatment-resistant organ rejection, evaluating and recording their responses to the treatment. In each case, treatment with the drug provided prompt rejection reversal, prolonged reductions in antibody levels and improved organ function with suppression of recurrent rejection for at least five months.
Jason Everly, PharmD, an oncology pharmacist in the transplant surgery division at UC and coauthor of the study, says the toxicities associated with this drug were predictable and manageable and were much less than those associated with other anti-cancer agents.
“We are pleased to see its toxicities are similar in transplant recipients suffering from treatment resistant mixed organ rejection,” he adds. “We hope it will be a viable therapeutic treatment option in this patient group.”
Woodle says although this data is promising, it is difficult to overestimate the implications of this drug.
“We have an immunosuppressant agent that for the first time can target antibody-producing plasma cells with an efficacy samilar to drugs that target T cells,” he says. “This has significant implications for transplant and autoimmune disease.”
Researchers are currently conducting four industry-supported trials to expand these findings. This study was investigator-initated.